Search results
Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?
Motley Fool· 1 year agoMost pharma investors are familiar with power players like Eli Lilly (NYSE: LLY) and Bristol Myers...
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
Motley Fool via Yahoo Finance· 2 months agoIf you aren't familiar with the Danish pharmaceutical company Novo Nordisk (NYSE: NVO), I bet you've...
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Motley Fool· 9 months agoWhen Joe Biden ran for president in 2020, he promised to allow Medicare to negotiate directly with...
2 Top Healthcare Stocks to Buy for the Long Haul
Motley Fool· 1 year agoLet's consider two of them: Bristol Myers Squibb (NYSE: BMY) and Novo Nordisk (NYSE: NVO). Bristol Myers is one of the largest pharmaceutical companies...
The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List
Investor's Business Daily· 9 months agoThere's a piece of bad news for Novo Nordisk's massively popular diabetes drug Ozempic in Medicare's...
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Motley Fool· 9 months agoAbout a year ago, President Joe Biden signed the Inflation Reduction Act into law. Among the many...
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Zacks via Yahoo Finance· 1 month agoFor Immediate Release Chicago, IL – April 26, 2024 – Zacks.com announces the list of stocks featured...
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
Reuters via Yahoo Finance· 1 year agoThe blood thinner Eliquis from Bristol Myers Squibb, Pfizer's breast cancer drug Ibrance and...
2 Pharma Stocks With Blockbuster Drugs on the Horizon
Motley Fool· 2 years agoAbbVie's Humira, used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic...
Merck Reverses Higher As Keytruda, Gardasil Outplay Covid Decline; Bristol Shares Dip
Investor's Business Daily· 1 year agoMerck topped Wall Street's first-quarter forecasts Thursday while Bristol Myers Squibb delivered a...